Posted by Michael Wonder on 30 Apr 2020
Teva Canada announces the launch of Ajovy for the preventive treatment of migraine in adults who have at least four migraine days per month
29 April 2020 - Ajovy is the first and only anti-CGRP treatment with both quarterly and monthly dosing for the preventive treatment of migraine in adults.
Teva Canada announced today that Health Canada has recently granted a notice of compliance to Ajovy (fremanezumab) 225 mg solution for subcutaneous injection in a pre-filled syringe for the preventive treatment of migraine in adults who have at least four migraine days per month.
Ajovy is the first and only anti-CGRP drug approved in Canada, the European Union, and the United States that offers quarterly or monthly dosing regimens for the prophylactic treatment of migraine.
